Abivax S.A.
ABVX
87.01
-1.21
-1.37%
Abivax S.A.
US · ABVX
#1658 by market cap
Listed 2023
87.01
-1.21
-1.37%
Live - 5344 symbols - heartbeat 130s ago
· 2026-10-08 07:00
Pre-market
85.90
-1.28%
After-hours
87.43
+0.48%
Overnight
86.04
-1.11%
- Market cap
- 7.59B
- P/E (TTM)i
- -14.58
- P/Bi
- 18.52
- EPSi
- -5.41
- Div yieldi
- 0.00%
- 52W posi
- 22%
Reader sentiment
Are you bullish or bearish on ABVX?
Anonymous reader poll. Unscientific, not investment advice.
About Abivax S.A.
Abivax SA engages in the sale, research, distribution, and development of biopharmaceutical products. It offers commercial and development products of anti-viral compounds and human vaccines. The commercialized products include vaccines for typhoid fever, meningococcus, and leptospirosis. The products under development include vaccines for chronic hepatitis B, ebola, and dengue virus. The company was founded by Philippe Pouletty on December 4, 2003 and is headquartered in Paris, France.
- Founded
- 2013
- CEO
- Mr. Marc de Garidel
- Employees
- 69
- Headquarters
- Paris, Ile-de-France, France
- Fiscal year end
- 12-31
- Website
- abivax.com
Company profile
- Exchange
- US
- Symbol
- ABVX
- Market-cap rank
- #1658
- Listing date
- 2023-10-20
- Market cap
- 7.59B
- Float cap
- 6.57B
- Shares out
- 87.27M
- Float shares
- 75.49M
Sectors & themes
Quote time 2026-10-08 07:00:07 · For reference only, not investment advice and not tailored to your situation.